Edition:
United Kingdom

MEI Pharma Inc (MEIP.OQ)

MEIP.OQ on NASDAQ Stock Exchange Capital Market

2.27USD
4:02pm GMT
Change (% chg)

$0.08 (+3.65%)
Prev Close
$2.19
Open
$2.17
Day's High
$2.27
Day's Low
$2.16
Volume
5,868
Avg. Vol
33,484
52-wk High
$3.26
52-wk Low
$1.49

Select another date:

Tue, Feb 13 2018

BRIEF-MEI Pharma Says Interim Data Review Supports Continuation Of ME-344 Clinical Study

* MEI PHARMA INTERIM DATA REVIEW SUPPORTS CONTINUATION OF CLINICAL STUDY EVALUATING ME-344 IN PATIENTS WITH BREAST CANCER

BRIEF-MEI Pharma Q2 Loss Per Share $0.16

* ‍AS OF DECEMBER 31, 2017, HAD $42.4 MILLION IN CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS, WITH NO OUTSTANDING DEBT​

BRIEF-Helsinn Group and MEI Pharma's Pracinostat receives orphan drug designation from European Medicines Agency

* HELSINN GROUP AND MEI PHARMA ANNOUNCE THAT PRACINOSTAT HAS RECEIVED ORPHAN DRUG DESIGNATION FROM THE EUROPEAN MEDICINES AGENCY FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) Source text for Eikon: Further company coverage:

BRIEF-MEI Pharma Announces FDA Clearance Of Investigational New Drug Application For CDK Inhibitor Voruciclib

* MEI PHARMA ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR CDK INHIBITOR VORUCICLIB

BRIEF-Mei Pharma enters into at-market equity offering sales agreement

* On Nov. 8, 2017, co entered into at--market equity offering sales agreement with Stifel, Nicolaus & Company, Incorporated, as sales agent​

BRIEF-Mei Pharma announces exclusive license agreement with Presage Biosciences for voruciclib

* Mei Pharma announces exclusive license agreement with Presage Biosciences for voruciclib, an oral, selective cdk inhibitor

Select another date: